# Vaccine Therapy in Treating Patients With Metastatic Melanoma

> **NCT00334776** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 6 (actual)

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** gp100:209-217(210M) peptide vaccine
- **BIOLOGICAL:** therapeutic autologous dendritic cells
- **BIOLOGICAL:** tyrosinase peptide

## Key facts

- **NCT ID:** NCT00334776
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334776, "Vaccine Therapy in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00334776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*